Poor
Non-Compliant
Patient Risk:
Moderate
Summary
Several mechanistic and treatment outcome statements in the AI claims are not supported by the provided FDA label text, with multiple details overstating beyond the label wording. Additionally, critical label sections (contraindications, warnings/boxed warnings, and key safety population/dosing details) are not addressed by the AI claims provided, preventing full on-label compliance for safety-critical content.
Category Scores
Accurate Statements
Griseofulvin is an antifungal medication.
Supported by the FDA label conceptually (Microbiology: mechanism and dermatophyte activity; INDICATIONS AND USAGE: dermatophyte infections).
Griseofulvin is prescribed to treat fungal infections of the skin, hair, and nails (dermatophytoses).
INDICATIONS AND USAGE: dermatophyte infections of the skin not adequately treated by topical therapy, hair and nails.
Griseofulvin is used to treat ringworm of the scalp (tinea capitis).
INDICATIONS AND USAGE: Tinea capitis.
Griseofulvin is used to treat ringworm of the body (tinea corporis).
INDICATIONS AND USAGE: Tinea corporis.
Griseofulvin is used to treat ringworm of the feet (tinea pedis).
INDICATIONS AND USAGE: Tinea pedis.
Griseofulvin is used to treat ringworm of the fingernails or toenails (onychomycosis).
Partially supported: INDICATIONS AND USAGE includes Tinea unguium, but the label specifies it is for certain fungal species; the claim does not reflect species restriction.
Griseofulvin is typically used when topical treatments have been ineffective.
INDICATIONS AND USAGE: skin infections not adequately treated by topical therapy.
Unsupported Statements
Griseofulvin 500 mg is marketed under the brand name Grifulvin V.
Absent from the provided label text.
Griseofulvin has been available under the brand names Fulvicin, Fulvicin P/G, and Gris-Peg.
Absent from the provided label text.
Griseofulvin binding disrupts mitotic spindle fibers in fungal cells.
The provided Microbiology section states binding to microtubular proteins required for mitosis; it does not explicitly describe 'mitotic spindle fibers' disruption.
Disruption of mitotic spindle fibers inhibits fungal cell division.
Not explicitly stated in the provided Microbiology text.
Inhibiting fungal cell division stops the growth and proliferation of fungi.
The provided label does not explicitly equate mitosis inhibition to stopping growth/proliferation using that phrasing.
Griseofulvin treatment allows the body's immune system to clear the infection.
No statement in INDICATIONS AND USAGE or other provided label text about immune-system clearance mechanism.
Griseofulvin is particularly effective against dermatophytes.
The label supports activity and indication for dermatophytes, but 'particularly effective' is stronger than the provided label wording.
Dermatophytes infect skin, hair, and nails.
The label lists dermatophyte infections of skin/hair/nails but does not define dermatophytes as organisms that infect those tissues.
Generic versions of griseofulvin are generally available due to expired original patents and regulatory approvals.
Not addressed in the provided FDA label text.
Contradictions
Important Omissions
Contraindications (e.g., porphyria or hepatocellular failure; hypersensitivity history; pregnancy-related contraindications) were not addressed by the AI claims.
Importance:
High
Warnings/precautions and safety-critical guidance were not addressed by the AI claims (provided label includes severe skin/hepatic adverse events reference).
Importance:
High
Dosage and administration safety details (adult/pediatric dosing ranges, continuation until eradication, and safety not established at higher doses) were not addressed by the AI claims.
Importance:
High
Use in specific populations (pregnancy contraindications, pediatric safety age limits) was not addressed by the AI claims.
Importance:
High
Safety Assessment
Potential Patient Risk:
Moderate
Mechanism/outcome statements are overstated beyond the provided label phrasing, and key safety-critical label content (contraindications, pregnancy/pediatric cautions, and dosing safety) is not covered by the claims, preventing safe on-label alignment.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Moderate |
Recommendation
Non-Compliant
Primary Issue
Multiple mechanistic and efficacy-mechanism claims are unsupported or overextended beyond the provided label wording, and critical safety sections are omitted from the AI claims.
Suggested Improvement
Revise mechanistic claims to match label wording (binding to microtubular proteins required for mitosis) without adding unsupported downstream details (spindle-fiber disruption, immune clearance, or explicit growth/proliferation stopping). Include label-supported safety-critical information: contraindications, pregnancy-related contraindications, pediatric age/safety statements, and key dosing/monitoring-relevant guidance from the label sections provided.